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ABSTRACT
Marburg variant of multiple sclerosis (MS) is a highly aggressive, fulminant demyelinating disease with very high morbidity
and mortality. Early diagnosis and aggressive management is vital to limit severe disability and improve the outcome.
We present a case of 35 years old male who presented with rapidly progressive demyelinating illness, leading to bed
bound status over the course of a month. He was treated aggressively with intravenous (IV) steroids, plasma exchange
(PLEX) and Mitoxantrone (MTX), leading to a remarkable recovery.
Key words: Multiple sclerosis, demyelinating, fulminant.
INTRODUCTION

not start treatment immediately and took 2 doses only.
10 days later, he presented to emergency department
with new onset right hemiparesis, right UMN facial palsy,
motor aphasia and acute confusional state. Repeat MR
imaging showed interval increase in size of previously
noted lesions plus new lesions suggestive of fulminant
multiple sclerosis vs ADEM (Fig.2). He was severely
disabled (EDSS 9) and was admitted to intensive care
unit for aggressive therapy. CSF examination and Visual
evoked potentials were also obtained (Table 1). He was
given remaining 3 doses of IV methylprednisolone (1000
mg) and was started on PLEX (250ml/kg divided over 7
sessions; day 1,2,3,5,7,9,11).

Marburg variant of MS or Fulminant multiple sclerosis
(FMS) is a rare but highly aggressive disease. It is
characterized by rapidly progressive deterioration of
neurological symptoms, sometimes, even weeks or
months after the first attack (1). This results in progressive
widespread white matter destruction in cerebral cortex
but may even extend to involve vital brainstem structures
(2,3)
. Management of FMS is very challenging as the
outcome in many cases is either severe disability or
death. Treatment options for FMS include high dose
corticosteroids, serial plasma exchange transfusions,
immunoglobulins and disease modifying agents
(Mitoxantrone and Cyclophosphamide) (4,5,6,7,8,9). Patients
also need intense involvement of various support
services to help them during periods of disability. We
present a case of acute FMS who showed relatively rapid
and effective recovery when treated early and
aggressively.

Table 1. Pertinent Investigations
Investigations
ESR
CBC
CRP
PSA
Creatinine
CSF analysis

n=582
Hb : 16.70 g/dl

Platelets :
211,000/µl

4.66 mg/L
0.728 ng/mL
0.76 mg/dL
WBCs: <5
Protein:
OG bands:
cells/µL,
81.3mg/dL
positive
ACE levels
<5.0 U/L
LFTs
T. Bilirubin: 0.7mg/dL, ALT: 24, Alk.
Phosphatase: 30U/L
Chem 7 (mEq/L)
Sodium: 133, Potassium: 3.9, Chloride: 99,
Bicarbonate: 21 D
C
VEP (visual
P100 values:
evoked potentials)
Right: 125.4 ms, Left: 130.8 ms
Vitreous examination No immune complexes seen in vitreous
CT chest, abdomen, Negative for malignancy /infection
and pelvis

CASE REPORT
A 35 years, otherwise healthy gentleman was seen in our
neurology clinic for sudden onset left hemiparesis,
dysarthria, diplopia and blurring of vision lasting a few
days followed by partial recovery. There was no history of
fever or antecedent infection. He underwent cranial MR
imaging which revealed multiple nodular lesions,
isointense on T1 and hyperintense on FLAIR and T2
weighted images suggesting a demyelinating disorder or
metastatic disease (Fig.1). He was prescribed IV
methylprednisolone 1gm once daily for 5 days. He did
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1 mm/hour
TLC : 10,000/µl

Aggressive speech therapy and physiotherapy were also
done. Metastatic workup was ordered with CT chest,
abdomen and pelvis as were other investigations that
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came to be negative for malignancy. ANA was not done.
Patient showed gradual improvement in his clinical
status and was discharged home 12 days later. He was
given IV Mitoxantrone (12mg/m2), first dose given on 12
day post admission and then once every 3 months.

and pons (D), largest one measuring 2.7×1.4 cm2.
They are iso-intense/hypointense on T1 (E) with subtle
peripheral contrast enhancement (F) and correspondingly
bright on FLAIR image with surrounding halo (G) and no
significant mass effect.

Table 2. Differences between MS and ADEM

First described nearly a century ago, Marburg variant of
MS is a rare, acute, monophasic and highly aggressive
form of MS, leading to severe morbidity or mortality
within a few weeks to months.1 Due to its atypical
clinical and radiographic features, it poses significant
diagnostic dilemma (14). It presents with a polysymptomatic,
monophasic illness (15) suggesting diffuse and extensive
CNS involvement.

Characteristics
Age
Antecedent infection
Encephalopathy
CSF pleocytosis
Oligoclonal bands
MR imaging
(gray matter involvement
Course
Disease modifying
therapy

ADEM
<8 years
usual
Common
Prominent
Absent
Common

MS
≥8-10 years
unusual
Uncommon
Uncommon
Present
Uncommon

Monophasic,
Multiphasic, progressive,
Non-progressive Relapsing & remitting
Not required
Required to prevent
relapses

A

On discharge, EDSS improved from 9 to 5. He was
followed in neurology clinic 3 months later with repeat
MR imaging which showed interval regression in the size
of previously noted lesions with no new activity (Fig.3).
He showed remarkable clinical improvement, walking
without support (EDSS 2) (Fig.4). He had no further
relapse at 3 months.

B

C

D

E

DISCUSSION
Multiple sclerosis is the most common, idiopathic,
inflammatory demyelinating disease of central nervous
system with a relapsing and remitting course (1)
Approximately 7% of patients may present with a
fulminant disease (10). Tumefactive multiple sclerosis
refers to large demyelinating lesions, typically 2 cm or
larger in size, with surrounding mass effect, perilesional
edema and open ring enhancement on gadolinium
contrast (11,12,13).

Figure 2. Follow up MR images obtained 10 days later
with new onset right hemiparesis and acute confusional
state. DWI (A and C), ADC (B and D)and axial FLAIR
images(E) showing development of new lesions and
interval increase in size of previously observed multiple
lesions which have become more confluent bilaterally.
Unlike classical MS, lesions occur simultaneously in all
affected areas with large zones of confluent
demyelination,(1,16) including cerebral hemisp- heres
and brainstem (17) High mortality is associated with this
variant especially with involvement of brainstem
structures, (12,18,19) necessitating intensive care for
aggressive management (15).First presentation of an
acute, fulminant demyelinating event is the most
common presentation in the course of tumefactive
MS,13 hence early and prompt recognition of disease
process and exclusion of infective, neoplastic, vasculitic and
granulomatous disorder is of paramount importance.
Figure 3. Follow up MR images of same patient
obtained at 3 months after resolution of acute neurological
dysfunction. Axial T1 pre (A), post contrast (B) and FLAIR
(C) images showing regression in size of previously noted
lesions with no abnormal post contrast enhancement.

Figure 1. Axial diffusion weighted images(DWI) of Brain
(A) and (C) showing multiple nodular lesions of diffusion
restriction in bilateral parietal periventricular and
subcortical regions, corresponding ADC images (B)
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A

B

Fig 4. Follow up of patient in neurology clinic 3 months
later.

C

We used Plasma exchange (PLEX) in this patient due to
financial constraints. Mitoxantrone is an immunomodulatory agent used as a disease modifying drug
(DMD) to improve neurological disability and delay
progression in relapsing remitting MS and secondary
progressive MS (21). Several randomized clinical trials
used 12mg/m2 dose administered once every 3
months (21). We have previously used mitoxantrone for
management of relapsing remitting MS (23) and as a
DMD for Fulminant MS.22 Though FMS is a disease of
severe morbidity and high mortality but better outcome
can be expected if treated promptly and aggressively
with disease modifying therapies early in the course of
the disease.

As our patient had no previous history of MS, it was
difficult to differentiate it from other varieties of
malignant demyelinating diseases especially ADEM.
However, historical data, CSF analysis and radiographic
characteristics of lesions suggested fulminant MS
(table 2) (20). Radiological images were almost diagnostic
of tumefactive demyelinating process based on size
(2cm or more), location (periventricular and juxtacortical)
and nature of lesions (confluent areas, mixed T2
weighted iso and hyperintensity of enhanced regions,
absence of cortical involvement and absence of a mass
effect) (14,15,21,22) The lesions can be multifocal (83%)
(as in our case) or unifocal (17%)(13) CSF analysis in our
patient revealed absence of pleocytosis with elevated
protein and presence of oligoclonal bands which is
present in 11% to 33% of tumefactive MS cases,(13)
favouring our diagnosis of tumefactive MS over ADEM. (23)
Biopsy of the lesions is not routinely recommended to
make a histological diagnosis. Standard treatment
approach for fulminant MS variants is similar to severe
relapses of MS. However, due to the rarity and high
mortality associated with Marburg variant of MS, only a
limited number of case reports have shown some
promising results for Plasma exchange and Mitoxantrone
as treatment for acute phase and prevention of further
relapses (4,5,24) There is one published study of
Fulminant MS from Pakistan also from our centre where
patients were treated with IV immunoglobulins followed
by Mitoxantrone, with good outcomes(22).

CONCLUSION
Due to limitation of resources in our country, PLEX
followed by Mitoxantrone may be a valuable option for
treatment of fulminant multiple sclerosis.
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